Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
- Positive momentum in new modalities and acquisitions like Metenova AB.
- Financially, a decrease in total revenue and gross profit in Q4 2023 compared to 2022.
- Improved cash position of $751.3 million at December 31, 2023.
- Financial guidance for FY 2024 with expected revenue of $620M - $650M and adjusted net income of $80M - $84M.
- Decrease in total revenue and gross profit in Q4 2023 compared to 2022.
- Loss from operations and net loss in Q4 2023.
- Challenging macro factors in China impacting the market.
Insights
The reported financial results from Repligen Corporation reflect a notable decrease in total and base revenue for both Q4 and the full year 2023 compared to the previous year. This decline is particularly significant given the life sciences sector's critical role in bioprocessing technology, which is typically characterized by steady growth due to ongoing demand for biopharmaceuticals.
While the company's book-to-bill ratio remains above 1, indicating a healthy order intake, the drop in revenue and gross profit margins suggests a potential slowdown in actual sales or challenges in cost management. The acquisition of Metenova and the launch of the TangenX® SC device are strategic moves to diversify offerings and could be key drivers for future growth, especially in the burgeoning cell and gene therapy markets.
However, the financial guidance for 2024 projects a further potential decrease or a marginal increase in revenue, which may raise concerns among investors about the company's growth trajectory. The emphasis on adjusted EBITDA margins and a significant difference between GAAP and non-GAAP measures may indicate underlying operational challenges.
Repligen's financial performance reveals a contraction in profitability, with both GAAP and non-GAAP gross profit and operating income declining year-over-year. The reported net loss in Q4 2023, as opposed to net income in the same quarter of the previous year, is a red flag that could impact investor sentiment.
The private convertible transaction of $600 million at a 1.00% interest rate is a strategic financial move, potentially aimed at strengthening the balance sheet and funding growth initiatives. Nevertheless, the immediate impact on earnings per share is negative and the benefits of this capital injection will need to be assessed over the coming quarters.
The cash position has improved, which provides some financial flexibility. However, the forecast for 2024, with only a slight potential increase in revenue at best, may not be enough to counterbalance the bearish indicators from the previous year's performance.
Repligen's focus on bioprocessing technologies for the life sciences industry is a strategic position within the biotech sector. The mention of positive momentum in new modalities, such as cell and gene therapies, indicates alignment with high-growth areas of biotechnology. The launch of the industry's first holder-free TFF device could represent a technological advancement with the potential to streamline bioprocessing workflows.
However, the reported results suggest that despite these strategic moves, the company is not immune to macroeconomic factors or market saturation. The mention of headwinds in China, a significant market for life sciences companies, could be indicative of broader global challenges. Investors would need to weigh the potential long-term benefits of Repligen's product innovations and market expansion against the current financial downturn.
- Reports fourth quarter revenue of
$156 million and full year revenue of$639 million - Continued strength in orders with fourth quarter book-to-bill ratio of 1.03
WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023. The company is also providing financial guidance for the full year 2024.
Tony J. Hunt, Chief Executive Officer of Repligen said, “During the fourth quarter, we again saw order strength, driven by our Filtration and Analytics franchises and continued momentum from new modality accounts, which reflects the differentiated nature of our products in this market. We are pleased to report that for the second quarter in a row, our book-to-bill ratio was above 1.0, at 1.03 for the fourth quarter. Revenue for the quarter came in as expected with a nice contribution from Metenova of
FOURTH QUARTER BUSINESS HIGHLIGHTS
- Positive momentum in new modalities, inclusive of cell and gene therapies, with fourth quarter revenue up
5% sequentially, and up9% year-over-year - Closed acquisition of mixing innovator Metenova AB, expanding our Fluid Management offering; achieved revenue target of
$5 million in the fourth quarter - Launched TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtration (TFF) device; a milestone achievement in the advancement of downstream flat sheet TFF technology for ultrafiltration and diafiltration (UF/DF)
- Strengthened our balance sheet through a private convertible transaction of
$600 million aggregate principal amount of1.00% convertible senior notes - Published our Sustainability report “Making an Impact”, highlighting the company’s progress across numerous environmental, social and governance (ESG) initiatives
FINANCIAL PERFORMANCE
- Revenue. For Q4 2023, total revenue was
$155.7 million , compared to$186.8 million for 2022. Base revenue (non-GAAP) for Q4 2023 was$142.1 million , compared to$163.0 million for Q4 2022.
For the full year 2023, total revenue was$638.8 million , compared to$801.5 million for 2022. Base revenue (non-GAAP) for 2023 was$599.1 million , compared to$660.5 million for 2022.
- Gross profit. For Q4 2023, our gross profit (GAAP) was
$67.6 million compared to$96.1 million for Q4 2022. Adjusted gross profit (non-GAAP) for Q4 2023 was$76.5 million compared to$96.1 million for Q4 2022. Gross profit (GAAP) includes$7.7 million in one-time restructuring charges, comprised primarily of inventory adjustments and including asset relocation and severance costs.
For the full year 2023, gross profit (GAAP) was$284.8 million , compared to$455.7 million for the full year 2022. Adjusted gross profit (non-GAAP) for the full year 2023 was$316.5 million , compared to$456.9 million for 2022.
- (Loss) Income from operations. For Q4 2023, loss from operations (GAAP) was (
$0.9) million , compared to income from operations of$48.8 million for Q4 2022. Adjusted income from operations (non-GAAP) for Q4 2023 was$18.8 million , compared to$41.1 million for Q4 2022.
For the full year 2023, income from operations (GAAP) was$54.6 million , compared to$224.7 million for the full year 2022. Adjusted income from operations (non-GAAP) for the full year 2023 was$94.3 million , compared to$232.2 million for 2022.
- Net (loss) income. For Q4 2023, net loss (GAAP) was (
$25.5) million , compared to net income (GAAP) of$48.7 million for Q4 2022. Adjusted net income (non-GAAP) for Q4 2023 was$18.8 million compared to$39.1 million for Q4 2022.
For the full year 2023, net income (GAAP) was$41.6 million , compared to$186.0 million for full year 2022. Adjusted net income (non-GAAP) for 2023 was$98.4 million compared to$188.6 million for 2022.
- (Loss) Earnings per share. For Q4 2023, loss per share (GAAP) was (
$0.46) per basic share and fully diluted basis, compared to$0.85 on a fully diluted basis for Q4 2022. Adjusted earnings per share (non-GAAP) for Q4 2023 was$0.33 on a fully diluted basis, compared to$0.68 for Q4 2022.
For the full year 2023, earnings per share (GAAP) was$0.74 on a fully diluted basis, compared to$3.24 for 2022. Adjusted earnings per share (non-GAAP) for 2023 was$1.75 on a fully diluted basis, compared to$3.28 for 2022.
MARGIN SUMMARY
| GAAP Margins | Q4 2023 | Q4 2022 | FY 2023 | FY 2022 |
| Gross Margin | ||||
| Operating (EBIT) Margin | ( |
| Adjusted (non-GAAP) Margins | Q4 2023 | Q4 2022 | FY 2023 | FY 2022 |
| Gross Margin | ||||
| Operating (EBIT) Margin | ||||
| EBITDA Margin | ||||
CASH POSITION
- Our cash, cash equivalents and short-term investments at December 31, 2023, were
$751.3 million , compared to$623.8 million at December 31, 2022.
FINANCIAL GUIDANCE FOR FISCAL YEAR 2024
Our financial guidance for the fiscal year 2024 is based on expectations for our existing business. Our GAAP and Adjusted (non-GAAP) guidance includes the expected impact of businesses acquired in 2023 (FlexBiosys and Metenova) and excludes the impact of any potential business acquisitions in 2024, and future fluctuations in foreign currency exchange rates.
| CURRENT GUIDANCE (at February 21, 2024) | ||
| FY 2024 | GAAP | Adjusted (non-GAAP) |
| Total Reported Revenue | ||
| Year-over-Year Change | ( | ( |
| Base Revenue Growth | - | ( |
| Gross Margin | ||
| Income from Operations | ||
| Operating Margin | ||
| Other Income (Expense) | ||
| Adjusted EBITDA Margin | - | |
| Tax Rate on Pre-Tax Income | ||
| Net Income | ||
| Earnings Per Share - Diluted | ||
Our non-GAAP net income guidance for the fiscal year 2024 reflects
Conference Call and Webcast Access
Repligen will host a conference call and webcast today, February 21, 2024, at 8:30 a.m. ET, to discuss fourth quarter 2023 financial results, corporate developments and financial guidance for the year 2024. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers or (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 from the U.S., (855) 669-9658 from Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 4526890.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
Non-GAAP Measures of Financial Performance
To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: book-to-bill ratios, base business revenue growth, adjusted gross profit, adjusted gross margin and adjusted operating margin; adjusted cost of sales; adjusted R&D expense; adjusted SG&A expense; adjusted pre-tax income; adjusted income from operations; adjusted net income; adjusted earnings per share-diluted; adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA margin. The Company provides base revenue and base revenue growth rates, which exclude COVID-related revenue, and the impact of acquisition revenue for current year periods that have no prior year comparables, to facilitate a comparison of its current revenue performance. The Company provides the impact of foreign currency translation, to enable determination of revenue growth rates at constant currency, which exclude the impact of foreign currency translation, in order to facilitate a comparison of its current revenue performance to its past revenue performance. To calculate the impact of foreign currency translation, the Company converts actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period.
The Company’s non-GAAP financial results and/or non-GAAP guidance exclude the impact of: inventory step-up charges; acquisition and integration costs; restructuring charges including the costs of severance; inventory adjustments and accelerated depreciation among other charges; contingent consideration related to the Company’s acquisitions; intangible amortization costs; loss on extinguishment of debt; non-cash interest expense related to the accretion of the debt discount; amortization of debt issuance costs related to Company’s convertible debt; foreign currency impact of certain intercompany loans; and, the related impact on tax of non-GAAP charges. These costs are excluded because management believes that such expenses do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.
NOTE:
All reconciliations of above GAAP figures (reported or guidance) to adjusted (non-GAAP) figures are detailed in the tables included later in this press release. When analyzing the Company’s operating performance and guidance investors should not consider non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.
Forward-Looking Statement
This release contains forward-looking statements, which are made pursuant to and in reliance upon the safe harbor provisions of federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this release which are not strictly historical statements, including, among others; any express or implied statements or guidance regarding current or future financial performance and position, including our year 2024 financial guidance and related assumptions; expected demand in the markets in which we operate (including the belief that such markets will improve and the impact of such improvement on our business); the expected performance of our business; planned efficiencies and results from our restructuring and rebalancing activities; the expected performance and success of our strategic partnerships and integration of our acquired businesses, constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” “projected,” “estimated” or “could” and similar expressions. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, risks associated with our restructuring activities and our ability to successfully rebalance our organization; our ability to successfully grow our bioprocessing business; our ability to manage through and predict headwinds, including to achieve our adjusted 2024 financial guidance; our ability to develop and commercialize products and the market acceptance of our products; our ability to successfully integrate any acquired businesses (including Metenova and FlexBiosys) into our business and achieve the expected benefits of such acquisitions; that demand for our products could continue to decline, which could adversely impact our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our compliance with all U.S. Food and Drug Administration and European Medicines Evaluation Agency regulations; the lasting effects of COVID-19 on our business operations and the operations of our customers and suppliers; our volatile stock price; and other risks detailed in Repligen’s filings with the U.S. Securities and Exchange Commission (the Commission), including Annual Report on Form 10-K for the year ended December 31, 2022 and in subsequently filed reports with the Commission, including our Quarterly Reports on Form 10-Q and current reports on Form 8-K, as well as our upcoming Annual Report on Form 10-K for the year ended December 31, 2023. Actual results may differ materially from those Repligen contemplated by these forward-looking statements; therefore, you should not rely on any of these forward-looking statements. These forward-looking statements reflect management’s current views, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and are based only on information currently available to us. Repligen does not undertake to update, whether written or oral, any of these forward-looking statements to reflect a change in its views or events or circumstances, whether as a result of new information, future development or otherwise, that occur after the date hereof except as required by law.
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
| REPLIGEN CORPORATION | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (Unaudited, amounts in thousands, except share and per share data) | |||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Revenue: | |||||||||||||||
| Product revenue | $ | 155,471 | $ | 186,515 | $ | 638,381 | $ | 801,183 | |||||||
| Royalty and other revenue | 272 | 247 | 383 | 353 | |||||||||||
| Total revenue | 155,743 | 186,762 | 638,764 | 801,536 | |||||||||||
| Costs and expenses: | |||||||||||||||
| Cost of product revenue | 88,136 | 90,700 | 353,922 | 345,830 | |||||||||||
| Research and development | 10,285 | 11,113 | 42,722 | 43,936 | |||||||||||
| Selling, general and administrative | 57,512 | 53,237 | 218,113 | 215,829 | |||||||||||
| Contingent consideration | 697 | (17,125 | ) | (30,569 | ) | (28,729 | ) | ||||||||
| 156,630 | 137,925 | 584,188 | 576,866 | ||||||||||||
| (Loss) Income from operations | (887 | ) | 48,837 | 54,576 | 224,670 | ||||||||||
| Investment income | 6,023 | 4,016 | 24,135 | 6,978 | |||||||||||
| Interest expense | (1,138 | ) | (270 | ) | (1,951 | ) | (1,162 | ) | |||||||
| Loss on extinguishment of debt | (12,676 | ) | - | (12,676 | ) | - | |||||||||
| Amortization of debt issuance costs* | (6,702 | ) | (455 | ) | (8,075 | ) | (1,815 | ) | |||||||
| Other income (expenses), net | 6,623 | 858 | 8,123 | (9,531 | ) | ||||||||||
| (Loss) income before income taxes | (8,757 | ) | 52,986 | 64,132 | 219,140 | ||||||||||
| Income tax provision | 16,731 | 4,257 | 22,555 | 33,181 | |||||||||||
| Net (loss) income | $ | (25,488 | ) | $ | 48,729 | $ | 41,577 | $ | 185,959 | ||||||
| (Loss) earnings per share: | |||||||||||||||
| Basic | $ | (0.46 | ) | $ | 0.88 | $ | 0.75 | $ | 3.35 | ||||||
| Diluted* | $ | (0.46 | ) | $ | 0.85 | $ | 0.74 | $ | 3.24 | ||||||
| Weighted average shares outstanding: | |||||||||||||||
| Basic | 55,815,666 | 55,542,248 | 55,719,860 | 55,460,232 | |||||||||||
| Diluted* | 55,815,666 | 57,105,172 | 56,377,319 | 57,455,275 | |||||||||||
| *Under ASU 2020-06, the Company is required to reflect the dilutive effect of the 2019 Notes by application of the if-converted method. Prior to filing the Second Supplemental Indenture on March 4, 2022, the Company had the option to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 (the date the Company adopted ASU 2020-06) to March 4, 2022, the Company included 3,474,429 shares in the denominator of the weighted average twelve months ended December 31, 2022 diluted EPS calculation. Subsequent to March 4, 2022, after the Second Supplemental Indenture became effective, the Company irrevocably elected to settle the conversion principal in cash and only the premium in shares of the Company's common stock. Therefore, from March 5, 2022 to March 31, 2022 the Company included 980,525 shares in the denominator of the weighted average twelve months ended December 31, 2022 diluted EPS calculation. Under the if-converted method, the Company was also required to exclude amortization of debt issuance cost and interest charges applicable to the convertible debt from the numerator of the diluted EPS calculation for the period from January 1, 2022 to March 4, 2022, assuming the interest on convertible debt was never recognized for that period. For the twelve months ended December 31, 2022 the Company excluded amortization of debt issuance costs and interest charges for the period January 1, 2022 to March 4, 2022 of | |||||||||||||||
| Balance Sheet Data: | December 31, 2023 | December 31, 2022 | |||||||||||||
| Cash, cash equivalents and marketable securities | $ | 751,323 | $ | 623,757 | |||||||||||
| Working capital | 952,881 | 593,922 | |||||||||||||
| Total assets | 2,824,411 | 2,524,658 | |||||||||||||
| Long-term obligations | 695,046 | 209,762 | |||||||||||||
| Accumulated earnings | 438,849 | 397,272 | |||||||||||||
| Stockholders' equity | 1,971,203 | 1,910,700 | |||||||||||||
| REPLIGEN CORPORATION | |||||||||||||||||||||
| RECONCILIATIONS OF GAAP to NON-GAAP FINANCIAL MEASURES | |||||||||||||||||||||
| (Unaudited, amounts in thousands, except percentage and per share data) | |||||||||||||||||||||
| Reconciliation of Reported Revenue Growth to Organic Revenue Growth (Non-GAAP) | |||||||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||
| 2023 | 2023 | ||||||||||||||||||||
| REPORTED REVENUE GROWTH | ( | ( | |||||||||||||||||||
| Less: Acquisition Growth | |||||||||||||||||||||
| Less: Currency Exchange | |||||||||||||||||||||
| ORGANIC REVENUE GROWTH (NON-GAAP) | ( | ( | |||||||||||||||||||
| Reconciliation of Total Revenue (GAAP) to Base Revenue (Non-GAAP) | |||||||||||||||||||||
| Three Months Ended December 31, | % Change | Twelve Months Ended December 31, | % Change | ||||||||||||||||||
| 2023 | 2022 (2) | 2023 v 2022 | 2023 | 2022 (2) | 2023 v 2022 | ||||||||||||||||
| GAAP TOTAL REVENUE | $ | 155,743 | $ | 186,762 | (17 | %) | $ | 638,764 | $ | 801,536 | (20 | %) | |||||||||
| COVID Revenue | (8,007 | ) | (23,802 | ) | (66 | %) | (32,216 | ) | (141,067 | ) | (77 | %) | |||||||||
| Inorganic M&A | (5,670 | ) | - | 100 | % | (7,433 | ) | - | 100 | % | |||||||||||
| BASE REVENUE (NON-GAAP) (1) | $ | 142,066 | $ | 162,960 | (13 | %) | $ | 599,115 | $ | 660,469 | (9 | %) | |||||||||
| Reconciliation of GAAP (Loss) Income from Operations to Adjusted Income from Operations (Non-GAAP) | ||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| GAAP (LOSS) INCOME FROM OPERATIONS | $ | (887 | ) | $ | 48,837 | $ | 54,576 | $ | 224,670 | |||||||
| ADJUSTMENTS TO (LOSS) INCOME FROM OPERATIONS: | ||||||||||||||||
| Inventory step-up charges | 1,238 | - | 1,238 | - | ||||||||||||
| Acquisition and integration costs | 934 | 2,111 | 5,861 | 9,253 | ||||||||||||
| Restructuring costs(3) | 8,188 | - | 32,200 | - | ||||||||||||
| Contingent consideration | 697 | (17,125 | ) | (30,569 | ) | (28,729 | ) | |||||||||
| Intangible amortization | 8,651 | 7,304 | 30,981 | 27,016 | ||||||||||||
| ADJUSTED INCOME FROM OPERATIONS (NON-GAAP) | $ | 18,821 | $ | 41,127 | $ | 94,287 | $ | 232,210 | ||||||||
| Reconciliation of GAAP Net (Loss) Income to Adjusted Net Income (Non-GAAP) | ||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| GAAP NET (LOSS) INCOME | $ | (25,488 | ) | $ | 48,729 | $ | 41,577 | $ | 185,959 | |||||||
| ADJUSTMENTS TO NET (LOSS) INCOME: | ||||||||||||||||
| Inventory step-up charges | 1,238 | - | 1,238 | - | ||||||||||||
| Acquisition and integration costs | 934 | 2,111 | 5,861 | 9,514 | ||||||||||||
| Restructuring costs(3) | 8,188 | - | 32,200 | - | ||||||||||||
| Contingent consideration | 697 | (17,125 | ) | (30,569 | ) | (28,729 | ) | |||||||||
| Intangible amortization | 8,651 | 7,304 | 30,981 | 27,016 | ||||||||||||
| Loss on extinguishment of debt | 12,676 | - | 12,676 | - | ||||||||||||
| Non-cash interest expense | 620 | - | 620 | - | ||||||||||||
| Amortization of debt issuance costs(4) | 6,702 | 455 | 8,075 | 1,815 | ||||||||||||
| Foreign currency impact of certain intercompany loans (5) | (7,743 | ) | - | (7,743 | ) | - | ||||||||||
| Tax effect of non-GAAP charges | 12,278 | (2,402 | ) | 3,485 | (7,002 | ) | ||||||||||
| ADJUSTED NET INCOME (NON-GAAP) | $ | 18,753 | $ | 39,072 | $ | 98,401 | $ | 188,573 | ||||||||
| Reconciliation of GAAP (Loss) Earnings Per Share to Adjusted Earnings Per Share (Non-GAAP) | ||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| GAAP (LOSS) EARNINGS PER SHARE - DILUTED(6) | $ | (0.46 | ) | $ | 0.85 | $ | 0.74 | $ | 3.24 | |||||||
| ADJUSTMENTS TO (LOSS) EARNINGS PER SHARE - DILUTED: | ||||||||||||||||
| Inventory step-up charges | 0.02 | - | 0.02 | - | ||||||||||||
| Acquisition and integration costs | 0.02 | 0.04 | 0.10 | 0.17 | ||||||||||||
| Restructuring costs(3) | 0.15 | - | 0.57 | - | ||||||||||||
| Contingent consideration | 0.01 | (0.30 | ) | (0.54 | ) | (0.50 | ) | |||||||||
| Intangible amortization | 0.15 | 0.13 | 0.55 | 0.47 | ||||||||||||
| Loss on extinguishment of debt | 0.22 | - | 0.22 | - | ||||||||||||
| Non-cash interest expense | 0.01 | - | 0.01 | - | ||||||||||||
| Amortization of debt issuance costs(4) | 0.12 | 0.01 | 0.14 | 0.03 | ||||||||||||
| Foreign currency impact of certain intercompany loans (5) | (0.14 | ) | - | (0.14 | ) | - | ||||||||||
| Tax effect of non-GAAP charges | 0.22 | (0.04 | ) | 0.06 | (0.12 | ) | ||||||||||
| ADJUSTED EARNINGS PER SHARE (NON-GAAP) - DILUTED(6) | $ | 0.33 | $ | 0.68 | $ | 1.75 | $ | 3.28 | ||||||||
| Totals may not add due to rounding. | ||||||||||||||||
| Reconciliation of GAAP Net (Loss) Income to Adjusted EBITDA (Non-GAAP) | ||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| GAAP NET (LOSS) INCOME | $ | (25,488 | ) | $ | 48,729 | $ | 41,577 | $ | 185,959 | |||||||
| ADJUSTMENTS: | ||||||||||||||||
| Investment income | (6,023 | ) | (4,016 | ) | (24,135 | ) | (6,978 | ) | ||||||||
| Interest expense | 1,138 | 270 | 1,951 | 1,162 | ||||||||||||
| Amortization of debt issuance costs | 6,702 | 455 | 8,075 | 1,815 | ||||||||||||
| Income tax (benefit) provision | 16,731 | 4,257 | 22,555 | 33,181 | ||||||||||||
| Depreciation | 8,464 | 7,049 | 36,994 | 23,859 | ||||||||||||
| Intangible amortization(7) | 8,679 | 7,331 | 31,091 | 27,126 | ||||||||||||
| EBITDA | 10,203 | 64,075 | 118,108 | 266,124 | ||||||||||||
| OTHER ADJUSTMENTS: | ||||||||||||||||
| Inventory step-up charges | 1,238 | - | 1,238 | - | ||||||||||||
| Acquisition and integration costs | 934 | 2,111 | 5,861 | 9,514 | ||||||||||||
| Restructuring (3)(8) | 8,188 | - | 28,384 | - | ||||||||||||
| Contingent consideration | 697 | (17,125 | ) | (30,569 | ) | (28,729 | ) | |||||||||
| Loss on extinguishment of debt | 12,676 | - | 12,676 | - | ||||||||||||
| Foreign currency impact of certain intercompany loans (5) | (7,743 | ) | - | (7,743 | ) | - | ||||||||||
| ADJUSTED EBITDA (NON-GAAP) | $ | 26,193 | $ | 49,061 | $ | 127,955 | $ | 246,909 | ||||||||
| Reconciliation of GAAP Cost of Sales to Adjusted Cost of Sales (Non-GAAP) | ||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| GAAP COST OF SALES | $ | 88,136 | $ | 90,700 | $ | 353,922 | $ | 345,830 | ||||||||
| ADJUSTMENT TO COST OF SALES: | ||||||||||||||||
| Inventory step-up charges | (1,238 | ) | - | (1,238 | ) | - | ||||||||||
| Acquisition and integration costs | (6 | ) | (33 | ) | (39 | ) | (1,234 | ) | ||||||||
| Restructuring(3) | (7,675 | ) | - | (30,386 | ) | - | ||||||||||
| ADJUSTED COST OF SALES (NON-GAAP) | $ | 79,217 | $ | 90,667 | $ | 322,259 | $ | 344,596 | ||||||||
| Reconciliation of GAAP R&D Expense to Adjusted R&D Expense (Non-GAAP) | ||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| GAAP R&D EXPENSE | $ | 10,285 | $ | 11,113 | $ | 42,722 | $ | 43,936 | ||||||||
| ADJUSTMENT TO R&D EXPENSE: | ||||||||||||||||
| Acquisition and integration costs | (2 | ) | (92 | ) | 5 | (658 | ) | |||||||||
| Restructuring(3) | (81 | ) | - | (116 | ) | - | ||||||||||
| ADJUSTED R&D EXPENSE (NON-GAAP) | $ | 10,202 | $ | 11,021 | $ | 42,611 | $ | 43,278 | ||||||||
| Reconciliation of GAAP SG&A Expense to Adjusted SG&A Expense (Non-GAAP) | ||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| GAAP SG&A EXPENSE | $ | 57,512 | $ | 53,237 | $ | 218,113 | $ | 215,829 | ||||||||
| ADJUSTMENTS TO SG&A EXPENSE: | ||||||||||||||||
| Acquisition and integration costs | (925 | ) | (1,986 | ) | (5,826 | ) | (7,361 | ) | ||||||||
| Restructuring(3) | (432 | ) | - | (1,698 | ) | - | ||||||||||
| Intangible amortization | (8,651 | ) | (7,304 | ) | (30,981 | ) | (27,016 | ) | ||||||||
| ADJUSTED SG&A EXPENSE (NON-GAAP) | $ | 47,504 | $ | 43,947 | $ | 179,608 | $ | 181,452 | ||||||||
| Reconciliation of GAAP Net Income Guidiance to Adjusted Net Income (Non-GAAP) Guidance | ||||||||||||||||
| Twelve months ending December 31, 2024 | ||||||||||||||||
| Low End | High End | |||||||||||||||
| GUIDANCE ON GAAP NET INCOME | $ | 26,000 | $ | 30,000 | ||||||||||||
| ADJUSTMENTS TO GUIDANCE ON NET INCOME: | ||||||||||||||||
| Acquisition and integration costs | 4,672 | 4,672 | ||||||||||||||
| Non-cash interest expense | 13,745 | 13,745 | ||||||||||||||
| Anticipated pre-tax amortization of acquisition-related intangible assets | 34,617 | 34,617 | ||||||||||||||
| Amortization of debt issuance costs | 1,887 | 1,887 | ||||||||||||||
| Contingent consideration | 11,000 | 11,000 | ||||||||||||||
| Tax effect of non-GAAP charges | (11,751 | ) | (11,751 | ) | ||||||||||||
| Guidance rounding adjustment | (170 | ) | (170 | ) | ||||||||||||
| GUIDANCE ON ADJUSTED NET INCOME (NON-GAAP) | $ | 80,000 | $ | 84,000 | ||||||||||||
| Totals may not add due to rounding. | ||||||||||||||||
| Reconciliation of GAAP Earnings Per Share Guidance to Adjusted Earnings Per Share (Non-GAAP) Guidance | ||||||||||||||||
| Twelve months ending December 31, 2024 | ||||||||||||||||
| Low End | High End | |||||||||||||||
| GUIDANCE ON EARNINGS PER SHARE - DILUTED | $ | 0.46 | $ | 0.53 | ||||||||||||
| ADJUSTMENTS TO GUIDANCE ON EARNINGS PER SHARE - DILUTED: | ||||||||||||||||
| Acquisition and integration costs | 0.08 | 0.08 | ||||||||||||||
| Non-cash interest expense | 0.24 | 0.24 | ||||||||||||||
| Anticipated pre-tax amortization of acquisition-related intangible assets | 0.61 | 0.61 | ||||||||||||||
| Amortization of debt issuance costs | 0.03 | 0.03 | ||||||||||||||
| Contingent consideration | 0.19 | 0.19 | ||||||||||||||
| Tax effect of non-GAAP charges | (0.21 | ) | (0.21 | ) | ||||||||||||
| Guidance rounding adjustment | (0.00 | ) | (0.00 | ) | ||||||||||||
| GUIDANCE ON ADJUSTED EARNINGS PER SHARE (NON-GAAP) - DILUTED | $ | 1.42 | $ | 1.49 | ||||||||||||
| Totals may not add due to rounding. | ||||||||||||||||
| FOOTNOTES FOR ALL TABLES ABOVE: | ||||||||||||||||
| (1) | Base revenue excludes COVID-related revenue and excludes acquisition-related revenue contribution in current periods for which there was no prior year comparables. | |||||||||||||||
| (2) | Prior year acquisition revenue moved to "Base" for current year vs. prior year comparative purposes. | |||||||||||||||
| (3) | In July 2023, we began restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations. In addition to the initial efforts contemplated in July, the Company continued further restructuring activities during the three months ended December 31, 2023. These activities in the fourth quarter primarily included the adjustment of finished goods and raw material inventory balances down to their net realizable value from continued evaluation of the analyses started in the third quarter, such as shelf-life stability tests. Where demand has reduced, the value of this inventory, mostly secured during the COVID-19 period, exceeded the projected requirements to be used before reaching their expiration date. In addition, restructuring activities included costs related to the consolidation of a portion of our manufacturing facilities between certain U.S. locations and severance & employee related costs. | |||||||||||||||
| (4) | The twelve months ended December 31, 2022 represented amortization of debt issuance costs for the period April 1, 2022 to December 31, 2022 in addition to the amortization of debt issuance costs for the period March 5, 2022 to March 31, 2022 after the Second Supplemental Indenture was filed. Debt issuance cost for the period January 1, 2022 to March 4, 2022 were already reflected in the GAAP net income per share - diluted EPS under the if-converted method of calculating diluted EPS for the twelve months ended December 31, 2022. | |||||||||||||||
| (5) | During the fourth quarter of 2023 we recorded foreign currency gains on certain intercompany loans of | |||||||||||||||
| (6) | GAAP loss per share - diluted for the three months ended December 31, 2023, was determined excluding the effect of 626,847 shares of dilutive shares as the impact of such shares would have been antidilutive due to the net loss for the period, while the adjusted earnings per share - diluted for the same period was determined based upon diluted shares of 56,442,512 shares. | |||||||||||||||
| (7) | Includes amortization of milestone payments in accordance with GAAP of | |||||||||||||||
| (8) | Excludes | |||||||||||||||
FAQ
What was Repligen Corporation's (RGEN) fourth quarter revenue for 2023?
What was the full year revenue for Repligen Corporation (RGEN) in 2023?
What acquisitions did Repligen Corporation (RGEN) close in the fourth quarter of 2023?
What is Repligen Corporation's (RGEN) financial guidance for fiscal year 2024?
